申请人:Hoffmann-La Roche Inc.
公开号:US05726191A1
公开(公告)日:1998-03-10
A compound of the formula ##STR1## wherein R.sup.1 is hydrogen or C.sub.1-6 -alkyl; R.sup.2 is C.sub.1-6 -alkyl or adamantyl; R.sup.3 is C.sub.1-6 -alkyl or hydroxy; or R.sup.2 and R.sup.3 taken together are --(CR.sup.6 R.sup.7).sub.n --; R.sup.4 is C.sub.2-8 -alkyl, C.sub.2-8 -alkenyl, C.sub.2-8 -alkynyl, --OCH.sub.2 R.sup.5 or C.sub.2-8 -alkanoyl; and hydrogen when R.sup.3 is hydroxy; R.sup.5 is C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl or C.sub.2-6 -alkynyl; R.sup.6 and R.sup.7 are hydrogen or C.sub.1-6 -alkyl; Y is oxygen or sulphur; and n is 3, 4 or 5, and pharmaceutically usable salts of carboxylic acids of formula I act as selective ligands of retinoic acid .gamma.-receptors and are useful for the treatment of epithelial lesions.
一种化合物的化学式为##STR1##其中R.sup.1是氢或C.sub.1-6-烷基;R.sup.2是C.sub.1-6-烷基或金刚烷基;R.sup.3是C.sub.1-6-烷基或羟基;或R.sup.2和R.sup.3共同为--(CR.sup.6R.sup.7).sub.n--;R.sup.4是C.sub.2-8-烷基,C.sub.2-8-烯基,C.sub.2-8-炔基,--OCH.sub.2R.sup.5或C.sub.2-8-酰基;当R.sup.3是羟基时为氢;R.sup.5是C.sub.1-6-烷基,C.sub.2-6-烯基或C.sub.2-6-炔基;R.sup.6和R.sup.7是氢或C.sub.1-6-烷基;Y是氧或硫;n为3、4或5,并且公式I的羧酸的药用盐作为视黄酸.gamma.-受体的选择性配体,可用于治疗上皮病变。